Stockreport

Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium

Advaxis, Inc.  (ADXS) 
Last advaxis, inc. earnings: 9/9 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.advaxis.com
PDF Median overall survival of 16.4 months for advanced prostate cancer patients with visceral metastases treated with ADXS-PSA in combination with KEYTRUDA® compared to an [Read more]